Dal Molin Alberto, Di Massimo Dino Stefano, Braggion Cesare, Bisogni Sofia, Rizzi Elena, D'Orazio Ciro, Di Toppa Maria Vittoria, Alghisi Federico, Cristadoro Simona, Carnovale Vincenzo, Festa Gabriella, Rampini Serena, Colombo Carla, Oneta Anna, Furnari Maria Lucia, Calamia Maria Antonietta, Zunino Maria Luisa, Tuccio Giuseppe, Spadea Vincenzo, Messore Barbara, Grosso Bianca, Festini Filippo
Nursing School, Biella Hospital, University of Piemonte Orientale, Italy.
J Vasc Access. 2012 Jul-Sep;13(3):290-5. doi: 10.5301/jva.5000036.
The aim of this study was to assess the incidence of late onset complications of totally implantable venous access devices (TIVAD) in patients with cystic fibrosis (CF) and to investigate possible associations between the rate of complications and different policies of TIVAD management.
A multicenter prospective cohort study was performed in 11 Italian CF Centers. Patients with CF and a TIVAD were recruited and followed-up.
The study commenced on May 2008 and ended on September 2010. Eighty subjects were studied (77.5% women--mean age 27.2 years). Eighteen late complications of ports were observed (22.5%; incidence 0.96 per 1000 days of observation): three lumen occlusions, seven catheter-related infections , three port-related venous thrombosis, in addition to five other complications. A statistically significant association was found between the onset of catheter-related infection and the presence of CF-related diabetes (CFRD) (P=.0064)
Our data suggest that TIVADs represent a safe and effective device for the intermittent IV administration of drugs in people with CF. However, people with CFRD have a higher risk of developing TIVAD-related infection.
本研究旨在评估囊性纤维化（CF）患者完全植入式静脉通路装置（TIVAD）迟发性并发症的发生率，并探讨并发症发生率与TIVAD不同管理策略之间的可能关联。
在11个意大利CF中心进行了一项多中心前瞻性队列研究。招募了患有CF且植入TIVAD的患者并进行随访。
研究于2008年5月开始，2010年9月结束。共研究了80名受试者（女性占77.5%，平均年龄27.2岁）。观察到18例端口迟发性并发症（22.5%；每1000天观察期的发生率为0.96）：3例管腔阻塞、7例导管相关感染、3例端口相关静脉血栓形成，此外还有5例其他并发症。发现导管相关感染的发生与CF相关糖尿病（CFRD）的存在之间存在统计学上的显著关联（P = 0.0064）。
我们的数据表明，TIVAD是CF患者间歇性静脉给药的一种安全有效的装置。然而，患有CFRD的患者发生TIVAD相关感染的风险更高。
